FDMT's lead candidate, 4D-150, is being developed for the treatment of wet AMD, a leading cause of vision loss in older adults. The company has reported data from its Phase 1/2 and 2b PRISM trials, ...
EMERYVILLE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
Numbers, letters and the background must be the correct size and colour and there must be no missing numbers or letters. The ...
Skyway and TruWeather Solutions are proud to announce the next phase of collaboration aimed at leading Advanced Air Mobility (AAM) operations through the integration of Skyway’s advanced navigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback